| Name | Title | Contact Details |
|---|
Outset is a pioneering medical technology company that always puts the patient before the machine. Our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. And to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. Because we believe a dialysis machine should be as easy to use as an everyday consumer product, Tablo was designed with simplicity in mind. One example is Tablo`s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. And with simplicity comes speed. We`ve set out to give people their time back. Tablo dramatically reduces the time involved in setting up and managing dialysis. There is simply less to do and less to learn.
Diabetes Centers of America is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We`ve pioneered digital behavioral medicine: a new approach to tackling the growing epidemic of type 2 diabetes, heart disease, and obesity. Our online programs combine world-class science, technology, and design to inspire and enable people everywhere to live free of chronic disease. Named one of Fast Company`s “50 Most Innovative Companies in the World,” our team includes passionate and talented individuals from Google, IDEO, Harvard, Stanford, and Columbia. Our approach has been embraced by major employers across the country, including Costco and Iron Mountain, as well as leading health plans, such as Kaiser Permanente and Humana.
Illinois Knights Templar Home is a Paxton, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ascendis Pharma is focused on creating drug candidates that are improved versions of existing drugs, yielding more effective, lower-risk drugs with new patent life. Our proprietary TransCon platform is the leading, most versatile transient conjugation technology and is utilized to create clinically superior prodrugs in therapeutic areas characterized by high unmet medical need. TransCon technology creates novel long acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. Ascendis Pharma has a diversified and balanced high-value pipeline, including internal programs and partnerships together with market leaders on their key projects.